National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Talazoparib (Talzenna®) HTA ID: 19032

Talazoparib is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2 mutations, who have HER2-negative locally advanced or metastatic breast cancer.

NCPE Assessment Process Complete
Rapid review commissioned 19/08/2019
Rapid review completed 03/09/2019
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of talazoparib compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 09/09/2019
Pre-submission consultation with Applicant 02/12/2019
Initial submission received from Applicant 02/03/2020
Complete submission received from Applicant 06/03/2020
Preliminary review sent to Applicant 24/04/2020
NCPE assessment re-commenced 05/06/2020
Factual accuracy sent to Applicant 14/08/2020
NCPE assessment re-commenced 21/08/2020
NCPE assessment completed 18/09/2020
NCPE assessment outcome The NCPE recommends that talazoparib (Talzenna®) not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement following confidential price negotiations May 2021.